H
Hiroto Yoshida
Researcher at Chugai Pharmaceutical Co.
Publications - 25
Citations - 1704
Hiroto Yoshida is an academic researcher from Chugai Pharmaceutical Co.. The author has contributed to research in topics: Arthritis & Interleukin 6. The author has an hindex of 13, co-authored 22 publications receiving 1460 citations.
Papers
More filters
Journal ArticleDOI
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
TL;DR: All clinical findings and animal models suggest that IL-6 plays a number of critical roles in the pathogenesis of autoimmune diseases.
Journal ArticleDOI
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis.
Satoshi Serada,Minoru Fujimoto,Masahiko Mihara,Nobuo Koike,Yoshiyuki Ohsugi,Shintaro Nomura,Hiroto Yoshida,Teppei Nishikawa,Fumitaka Terabe,Tomoharu Ohkawara,Tsuyoshi Takahashi,Barry Ripley,Akihiro Kimura,Tadamitsu Kishimoto,Tetsuji Naka +14 more
TL;DR: Findings indicate that anti-IL-6R mAb treatment might represent a novel therapy for human MS through the inhibition of the development of MOG-peptide-specific Th17 cells and Th1 cells, which in turn leads to reduced infiltration of T cells into the CNS.
Journal ArticleDOI
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Minoru Fujimoto,Satoshi Serada,Masahiko Mihara,Yasushi Uchiyama,Hiroto Yoshida,Nobuo Koike,Yoshiyuki Ohsugi,Teppei Nishikawa,Barry Ripley,Akihiro Kimura,Tadamitsu Kishimoto,Tetsuji Naka +11 more
TL;DR: The findings suggest that IL-6 blockade in rheumatoid arthritis in human is also likely to involve a therapeutic mechanism distinct from that of TNF blockade and thus may represent an alternative therapy for patients in whom the disease is refractory to T NF blockade.
Journal ArticleDOI
Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor
TL;DR: It is concluded that IL6 blockade normalises reduced lipid levels caused by IL6, but does not affect normal lipid metabolism.
Journal ArticleDOI
Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule.
TL;DR: IL-6 signaling plays an important role in inflammatory cell migration by increasing the rate of cell adhesion and by inducing chemokine production in inflamed joints.